Feature | May 19, 2014

Pacemaker, Defibrillator Patients Adhering to Remote Monitoring Saw More Than Double Survival Rate

Data presented during at Heart Rhythm 2014 is industry’s largest study of remote management of pacemaker patients

May 19, 2014 — St. Jude Medical announced that data presented during a late-breaking clinical trial session at the 2014 annual scientific sessions of the Heart Rhythm Society (HRS) found an association between adherence to remote monitoring with the Merlin remote monitoring system and a reduction in patient mortality. Results from more than 260,000 patients implanted with either pacemakers or defibrillators demonstrated that patients with high adherence to remote monitoring had more than twice (2.4x) the probability of survival than that of patients without remote monitoring.

The prospective, observational study of U.S. patients also found that the greater the adherence to remote monitoring, the better the patient fared. Patients with high adherence to remote monitoring — measured as weekly transmission of patient data from the [email protected] System to the Merlin.net patient care network at least 75 percent of the time — overall had a 58 percent reduced likelihood of mortality than patients not using remote monitoring and a 35 percent reduced likelihood of mortality than patients with low remote monitoring. Though there was geographic variability, socioeconomic factors were not associated with remote monitoring use.

“This study is the first of its kind to find increased survival when remote monitoring is utilized in pacemaker patients,” said Suneet Mittal, M.D., director of EP at the Valley Hospital Health System of N.Y. and N.J. “Furthermore, our data suggest that, irrespective of whether a patient has a pacemaker or defibrillator, higher use of remote monitoring is associated with better survival. Although these associations require further investigation, these important observations should have significant implications for individual patient care and best-practice guidelines.”

All St. Jude Medical U.S. Food and Drug Administration (FDA) approved implantable cardiac devices capable of radiofrequency (RF) remote monitoring were included in the study, which had a cohort of 262,564. This is the largest study to date of remote monitoring pacemaker patients, and one of the largest for remote monitoring overall.

“Patients with implanted cardiac devices are typically required to visit doctors’ offices several times per year to have their device performance checked, which for many can be impractical. This new research demonstrates that the Merlin patient care system not only adds convenience for physicians and patients, it helps patients to live longer,” said Mark D. Carlson, M.D., chief medical officer for St. Jude Medical.

For more information: www.sjm.com

Related Content

CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe
News | EP Lab| September 27, 2016
In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement...
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
Overlay Init